Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aligos Therapeutics stock

Own Aligos Therapeutics stock in just a few minutes.

Aligos Therapeutics, Inc is a biotechnology business based in the US. Aligos Therapeutics shares (ALGS) are listed on the NASDAQ and all prices are listed in US Dollars. Aligos Therapeutics employs 74 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Aligos Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALGS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aligos Therapeutics share price

Use our graph to track the performance of ALGS stocks over time.

Aligos Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$12.82 - $37.51
50-day moving average $22.90
200-day moving average $23.26
Wall St. target price$34.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Aligos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aligos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aligos Therapeutics financials

Gross profit TTM $0
Return on assets TTM -29.72%
Return on equity TTM -64.37%
Profit margin 0%
Book value N/A
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Aligos Therapeutics shares

There are currently 1.6 million Aligos Therapeutics shares held short by investors – that's known as Aligos Therapeutics's "short interest". This figure is 3.4% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Aligos Therapeutics shares can be evaluated.

Aligos Therapeutics's "short interest ratio" (SIR)

Aligos Therapeutics's "short interest ratio" (SIR) is the quantity of Aligos Therapeutics shares currently shorted divided by the average quantity of Aligos Therapeutics shares traded daily (recently around 57474.15649677). Aligos Therapeutics's SIR currently stands at 27.86. In other words for every 100,000 Aligos Therapeutics shares traded daily on the market, roughly 27860 shares are currently held short.

To gain some more context, you can compare Aligos Therapeutics's short interest ratio against those of similar companies.

However Aligos Therapeutics's short interest can also be evaluated against the total number of Aligos Therapeutics shares, or, against the total number of tradable Aligos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aligos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aligos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0459% of the tradable shares (for every 100,000 tradable Aligos Therapeutics shares, roughly 46 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Aligos Therapeutics.

Find out more about how you can short Aligos Therapeutics stock.

Aligos Therapeutics share dividends

We're not expecting Aligos Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Aligos Therapeutics overview

Aligos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co. , Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site